Increased Hepatic Secretion of Very-Low-Density Lipoprotein Apolipoprotein B-100 in Obesity: A Stable Isotope Study
The DOI matches its Crossref record.
Abstract
1. We measured the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 (VLDL apoB) using a stable-isotope gas chromatography—mass spectrometry method in six obese subjects [three males, three females, age 41.5 ± 3.4 years (mean ± SEM), weight 105.0 ± 4.8 kg, plasma total cholesterol concentration 6.2 ± 0.4 mmol/l, triacylglycerol 2.8 ± 0.8 mmol/l, high-density lipoprotein cholesterol 1.0 ± 0.2 mmol/l] and six lean control subjects (three males, three females, age 41.8 ± 3.7 years, weight 68.2 ± 4.9 kg, total cholesterol concentration 4.5 ± 0.3 mmol/l, triacylglycerol 0.8 ± 0.2 mmol/l, high-density lipoprotein cholesterol 1.3 ± 0.1 mmol/l). 2. Plasma total cholesterol, triacylglycerol and mevalonic acid (an index of cholesterol synthesis in vivo) concentrations were significantly higher in the obese subjects than in control subjects (P = 0.02, P = 0.03, P = 0.04, respectively). VLDL apoB pool size and absolute secretion rate were significantly higher in the obese subjects than in control subjects (323.4 ± 99.8 mg versus 53.6 ± 17.1 mg, P = 0.004; and 42.3 ± 13.8 mg kg fat-free mass−1 day−1 versus 10.7 ± 0.4 mg kg fat-free mass−1 day−1, P = 0.01), but there was no significant difference in the fractional catabolic rate of VLDL apoB. 3. After pooling obese and control data, there was a significant positive association between VLDL apoB absolute secretion rate and (i) fat mass (r = 0.71, P = 0.009), (ii) plasma total cholesterol (r = 0.66, P = 0.019), (iii) triacylglycerol (r = 0.72, P = 0.008), (iv) total apolipoprotein B-100 (r = 0.77, P = 0.02), (v) mevalonic acid (r = 0.81, P < 0.001), (vi) fasting insulin (r = 0.61, P = 0.03) and (vii) fasting C-peptide (r = 0.70, P = 0.01) concentrations. There was also a significant positive association between plasma insulin and plasma mevalonic acid concentrations (r = 0.59, P = 0.04). The association between VLDL apoB absolute secretion rate and plasma mevalonic acid concentration remained significant after adjusting for plasma insulin concentration (r = 0.83, P = 0.01); however plasma insulin concentration was no longer associated with VLDL apoB absolute secretion rate (P = 0.40). 4. We conclude that increased hepatic secretion of VLDL apoB contributes to the elevated lipid concentrations observed in obesity. We suggest that increased secretion of this apolipoprotein may be a consequence of resistance to the inhibitory effect of insulin on VLDL apoB secretion and may be partly mediated by increased cholesterol synthesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sniderman, A. D., Scantlebury, T., & Cianflone, K. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00014 · Cited by 336
Fish oil — How does it reduce plasma triglycerides?
Shearer, G. C., Savinova, O. V., & Harris, W. S. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.011 · Cited by 285
“The former has been demonstrated in genetic dyslipidemias such as familial hypercholesterolemia [26, 27], familial combined hyperlipidemia [28, 29], but also in more common contexts such as obesity [30] and insulin resistance [31-34] with overproduction being confined primarily to VLDL1 (the largest VLDL particles).”
BackgroundChan, D. C., Watts, G. F., Barrett, P. H. R., Beilin, L. J., Redgrave, T. G., & Mori, T. A. (2002) · Diabetes · doi:10.2337/diabetes.51.8.2377 · Cited by 160
Self-citationVergès, B., Duvillard, L., Pais de Barros, J. P., Bouillet, B., Baillot-Rudoni, S., Rouland, A., Sberna, A.-L., Petit, J.-M., Degrace, P., & Demizieux, L. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.310990 · Cited by 75
de Beer, F., Stalenhoef, A. F. H., Hoogerbrugge, N., Kastelein, J. J. P., Gevers Leuven, J. A., van Duijn, C. M., Havekes, L. M., & Smelt, A. H. M. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq0202.102919 · Cited by 74
METABOLIC COMPLICATIONS OF OBESITY
Sheehan, M. T., & Jensen, M. D. (2000) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70226-1 · Cited by 68
Hoffer, M. J. V., Niththyananthan, S., Naoumova, R. P., Kibirige, M. S., Frants, R. R., Havekes, L. M., & Thompson, G. R. (1996) · Atherosclerosis · doi:10.1016/0021-9150(96)05819-4 · Cited by 32
Self-citation
Metadata
- Authors
- Cummings, M. H., Watts, G. F., Pal, C., Umpleby, M., Hennessy, T. R., Naoumova, R., & Sönksen, P. H.
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 1995-02-01
- Volume
- 88
- Issue
- 2
- Pages
- 225-233
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W2430449851
- Cited by
- 73
- References
- 0
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.